CoChat

Gene Therapy for Lipoprotein Lipase Deficiency: Working Toward Clinical Application

Rip, Jaap, Nierman, Melchior C., Sierts, Jeroen A., Petersen, Wilma, Den Oever, Karin Van, Raalte, Daniel Van, Ross, Colin J.D., Hayden, Michael R., Bakker, Andrew C., Dijkhuizen, Paul, Hermens, Wim T., Twisk, Jaap, Stroes, Erik, Kastelein, John J.P., Kuivenhoven, Jan Albert, Meulenberg, Janneke M. · 2005 · Human Gene Therapy
Cited by 63

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Lipoprotein lipase (LPL) deficiency causes hypertriglyceridemia and recurrent, potentially life-threatening pancreatitis. There currently is no adequate treatment for this disease. Previously, we showed that intramuscular administration of an adeno-associated virus serotype 1 (AAV1) vector encoding the human LPL(S447X) variant cDNA (AAV1-LPL(S447X)) normalized the dyslipidemia of LPL-/- mice for more than 1 year. In preparation for a clinical trial, we evaluated the safety and biodistribution of AAV1-LPL(S447X) in wild-type mice and fully characterized six LPL-deficient patients. Toxicological analysis in mice showed that intramuscular administration was well tolerated. Acute inflammatory response markers were transiently increased, and anti- AAV1 antibodies were generated. Histological analyses indicated a dose-dependent reversible spleen hyperplasia, and myositis at the injection sites. Biodistribution data showed short-term vector leakage from injection sites into the circulation, followed by liver-mediated clearance. Persistence of vector DNA was limited to the injected muscle and draining lymph nodes, and spread to reproductive organs was limited. Characterization of LPL-deficient patients showed that all patients presented with hypertriglyceridemia and recurrent pancreatitis. LPL catalytic activity was absent, but LPL protein levels were 20-100% of normal. Myoblasts derived from skeletal muscle biopsies of these patients were efficiently transduced by AAV1-LPL(S447X) and secreted active LPL. These data support the initiation of a clinical trial in LPL-deficient patients, for which regulatory approval has been granted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/hum.2005.16.1276

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 63

Metadata

Authors
Rip, J., Nierman, M. C., Sierts, J. A., Petersen, W., Den Oever, K. V., Raalte, D. V., Ross, C. J. D., Hayden, M. R., Bakker, A. C., Dijkhuizen, P., Hermens, W. T., Twisk, J., Stroes, E., Kastelein, J. J. P., Kuivenhoven, J. A., & Meulenberg, J. M.
Venue
Human Gene Therapy
Published
2005-11
Volume
16
Issue
11
Pages
1276-1286
ISSN
  • 1043-0342 (ISSN-L)
  • 1557-7422
OpenAlex
W2097092564
Cited by
63
References
5
FWCI
3.19
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene Therapy for Lipoprotein Lipase Deficiency: Working Toward Clinical Application. https://app.cochat.ai/papers/10.1089/hum.2005.16.1276
The paper
Rip, J., Nierman, M. C., Sierts, J. A., Petersen, W., Den Oever, K. V., Raalte, D. V., Ross, C. J. D., Hayden, M. R., Bakker, A. C., Dijkhuizen, P., Hermens, W. T., Twisk, J., Stroes, E., Kastelein, J. J. P., Kuivenhoven, J. A., & Meulenberg, J. M. (2005). Gene Therapy for Lipoprotein Lipase Deficiency: Working Toward Clinical Application. Human Gene Therapy. https://doi.org/10.1089/hum.2005.16.1276

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.